Claims for Patent: 8,637,026

Summary for Patent: 8,637,026

Title:	Anti-C35 antibody combination therapies and methods
Abstract:	The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and either at least one HER2 or at least one EGFR antibody. In some embodiments, the antibodies are administered with a therapeutic agent. The present invention is further directed to C35, HER2 and EGFR antibodies useful in these methods.
Inventor(s):	Zauderer; Maurice (Pittsford, NY), Evans; Elizabeth E. (Bloomfield, NY)
Assignee:	Vaccinex, Inc. (Rochester, NY)
Application Number:	12/810,743
Patent Claims:	1. A method of killing cancer cells that express C35 and HER2, said method comprising administering to said cells: (a) an amount of an anti-C35 antibody or antigen binding fragment thereof that specifically binds C35; and (b) an amount of trastuzumab, wherein said amount of anti-C35 antibody and said amount of said trastuzumab is effective for killing said cancer cells. 2. The method of claim 1 further comprising (c) administering an amount of a therapeutic agent. 3. The method of claim 2, wherein said therapeutic agent is a chemotherapeutic agent. 4. The method of claim 3, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, paclitaxel, adriamycin, docetaxel, taxotere, gemcitabine, and vinorelbine. 5. The method of claim 2, wherein said therapeutic agent is administered prior to administering at least one of said anti-C35 antibody and said trastuzumab. 6. The method of claim 2, wherein said therapeutic agent is administered after administering at least one of said anti-C35 antibody and said trastuzumab. 7. The method of claim 2, wherein said therapeutic agent is administered concurrently with at least one of said anti-C35 antibody and said trastuzumab. 8. The method of claim 1, wherein said anti-C35 antibody is selected from the group consisting of 1F2, 1B3, MAbc0009, MAb 163, MAb 165, MAb 171, antigen binding fragments, variants and derivatives thereof that retain the binding specificity for C35, and any combination thereof. 9. The method of claim 8, wherein said anti-C35 antibody is 1F2 or a variant or derivative thereof that retains binding specificity for C35. 10. The method of claim 9, wherein said anti-C35 antibody is 1F2. 11. The method of claim 1, wherein said cancer cells are selected from the group consisting of breast cancer cells, liver cancer cells, ovarian cancer cells, bladder cancer cells, lung cancer cells, prostate cancer cells, pancreatic cancer cells, colon cancer cells, and melanoma cells. 12. The method of claim 11, wherein said cancer cells are breast cancer cells. 13. The method of claim 1, wherein said anti-C35 antibody and said trastuzumab are administered concurrently. 14. The method of claim 1, wherein said anti-C35 antibody and said trastuzumab are administered sequentially.

Details for Patent 8,637,026

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-12-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-12-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-12-26